Momenta Phama (MNTA) Misses Q4 EPS by 29c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. NDAQ

Go back to Momenta Phama (MNTA) Misses Q4 EPS by 29c, Revenues Beat

Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

February 26, 2020 7:00 AM EST

-- Reported favorable interim data from Phase 1/2 study of M254 in ITP, supporting expansion of Part B; expect to report updated data in Q2 2020 and launch additional Phase 2 study in CIDP in Q4 2020 --

-- Target enrollment completed in nipocalimab Phase 2 Vivacity-MG study; top-line proof-of-concept results expected in Q3 2020 --

-- Expanded pipeline with nomination of M267, a new SIFbody development candidate targeting CD38; plan to initiate IND-enabling studies in 2020 --

-- Ended 2019 with a cash position of $545.1 million --

CAMBRIDGE, Mass., Feb. 26,... More